David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Carol Ho Yi Fong, Chun Yiu Law, Eunice Ka Hong Leung, Kelvin Kai Wang To, Kathryn Choon Beng Tan, Yu Cho Woo, Ching Wan Lam, Ivan Fan Ngai Hung, Karen Siu Ling Lam
Endocrinol Metab. 2021;36(3):582-589. Published online June 8, 2021
Background The occurrence of Graves’ disease and Hashimoto thyroiditis after coronavirus disease 2019 (COVID-19) raised concerns that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may trigger thyroid autoimmunity. We aimed to address the current uncertainties regarding incident thyroid dysfunction and autoimmunity among COVID-19 survivors.
Methods We included consecutive adult COVID-19 patients without known thyroid disorders, who were admitted to Queen Mary Hospital from July 21 to September 21, 2020 and had serum levels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine (fT3), and anti-thyroid antibodies measured both on admission and at 3 months.
Results In total, 122 patients were included. Among 20 patients with abnormal thyroid function tests (TFTs) on admission (mostly low fT3), 15 recovered. Among 102 patients with initial normal TFTs, two had new-onset abnormalities that could represent different phases of thyroiditis. Among 104 patients whose anti-thyroid antibody titers were reassessed, we observed increases in anti-thyroid peroxidase (TPO) (P<0.001) and anti-thyroglobulin (P<0.001), but not anti-thyroid stimulating hormone receptor titers (P=0.486). Of 82 patients with negative anti-TPO findings at baseline, 16 had a significant interval increase in anti-TPO titer by >12 U, and four became anti-TPO-positive. Worse baseline clinical severity (P=0.018), elevated C-reactive protein during hospitalization (P=0.033), and higher baseline anti-TPO titer (P=0.005) were associated with a significant increase in anti-TPO titer.
Conclusion Most patients with thyroid dysfunction on admission recovered during convalescence. Abnormal TFTs suggestive of thyroiditis occurred during convalescence, but infrequently. Importantly, our novel observation of an increase in anti-thyroid antibody titers post-COVID-19 warrants further follow-up for incident thyroid dysfunction among COVID-19 survivors.
Citations
Citations to this article as recorded by
T Cell Receptor Sequences Amplified during Severe COVID-19 and Multisystem Inflammatory Syndrome in Children Mimic SARS-CoV-2, Its Bacterial Co-Infections and Host Autoantigens Robert Root-Bernstein, Elizabeth Churchill, Shelby Oliverio International Journal of Molecular Sciences.2023; 24(2): 1335. CrossRef
A Literature Review on SARS-CoV-2 and Other Viruses in Thyroid Disorders: Environmental Triggers or No-Guilty Bystanders? Francesca Gorini, Cristina Vassalle International Journal of Environmental Research and Public Health.2023; 20(3): 2389. CrossRef
Thyroid dysfunction as a long-term post-COVID-19 complication in mild-to-moderate COVID-19 Vesselina Yanachkova, Teodora Stankova, Radiana Staynova Biotechnology & Biotechnological Equipment.2023; 37(1): 194. CrossRef
The Influence of SARS-CoV-2 Infection on the Thyroid Gland Aleksandra Piekarska, Marta Góral, Marta Kozula, Aleksandra Jawiarczyk-Przybyłowska, Katarzyna Zawadzka, Marek Bolanowski Biomedicines.2023; 11(2): 614. CrossRef
Thyroid Function Abnormalities and Outcomes in Hospitalized Patients
with COVID-19 Infection: A Cross-Sectional Study Deepika Patel, Dukhabandhu Naik, Sadishkumar Kamalanathan, Kadhiravan Tamilarasu, Jayaprakash Sahoo, Ayan Roy, Chandhana Merugu, Varun Suryadevara Hormone and Metabolic Research.2023; 55(03): 169. CrossRef
The Spectrum of Thyroid Function Tests and Autoantibodies During Hospitalization and After Six Months of Discharge in COVID-19 Patients: Does COVID-19 Trigger Autoimmunity? Ziynet Alphan Uc, Pinar Yagcı, Zelal Adibelli, Cevdet Duran Endocrine Research.2023; : 1. CrossRef
Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study Alessandro Rossini, Sara Cassibba, Francesca Perticone, Simone Vasilij Benatti, Serena Venturelli, Greta Carioli, Arianna Ghirardi, Marco Rizzi, Tiziano Barbui, Roberto Trevisan, Silvia Ippolito Frontiers in Endocrinology.2023;[Epub] CrossRef
A prospective follow-up of thyroid volume and thyroiditis features on ultrasonography among survivors of predominantly mild to moderate COVID-19 Man Him Matrix Fung, David Tak Wai Lui, Keith Wan Hang Chiu, Sherman Haynam Lee, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Connie Hong Nin Loong, Chun Yiu Law, Kelvin Kai Wang To, Ching W PeerJ.2023; 11: e15034. CrossRef
Autoimmune complications of COVID‐19 Niloufar Yazdanpanah, Nima Rezaei Journal of Medical Virology.2022; 94(1): 54. CrossRef
The Independent Association of TSH and Free Triiodothyronine Levels With Lymphocyte Counts Among COVID-19 Patients David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Chloe Yu Yan Cheung, Carol Ho Yi Fong, Chun Yiu Law, Kelvin Kai Wang To, Ching Wan Lam, Kathryn Choon Beng Tan, Yu Cho Woo, Ivan Fan Ngai Hung, Frontiers in Endocrinology.2022;[Epub] CrossRef
Comment on Khunti et al. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care 2021;44:2645–2655 Carmine Gazzaruso, Adriana Coppola, Pietro Gallotti, Ileana Terruzzi, Tiziana Montalcini, Livio Luzi Diabetes Care.2022; 45(2): e45. CrossRef
The potential impact of COVID-19 on thyroid gland volumes among COVID-19 survivors Emre Urhan, Zuleyha Karaca, Canan Sehit Kara, Zeynep Ture Yuce, Kursad Unluhizarci Endocrine.2022; 76(3): 635. CrossRef
Systematic review of COVID-19 and autoimmune thyroiditis Esra Tutal, Resat Ozaras, Hakan Leblebicioglu Travel Medicine and Infectious Disease.2022; 47: 102314. CrossRef
The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea Diagnostics.2022; 12(4): 960. CrossRef
Should we expect a wave of type 1 diabetes following SARS‐CoV‐2 pandemic? Laura Montefusco, Andrea Mario Bolla, Paolo Fiorina Diabetes/Metabolism Research and Reviews.2022;[Epub] CrossRef
COVID-19 and Thyroid Function: A Bi-Directional Two-Sample Mendelian Randomization Study Gloria Hoi-Yee Li, Ching-Man Tang, Ching-Lung Cheung Thyroid.2022; 32(9): 1037. CrossRef
Development of a prediction score (ThyroCOVID) for identifying abnormal thyroid function in COVID-19 patients D. T. W. Lui, C. H. Lee, W. S. Chow, A. C. H. Lee, A. R. Tam, C. Y. Y. Cheung, C. H. Y. Fong, S. T. M. Kwok, C. Y. Law, K. K. W. To, C. W. Lam, K. C. B. Tan, Y. C. Woo, I. F. N. Hung, K. S. L. Lam Journal of Endocrinological Investigation.2022; 45(11): 2149. CrossRef
Symptomatic Bradycardia Manifesting as Acute Hypothyroidism Following COVID-19 Infection: A Case Report Jaydip Desai, Arsh N Patel, Courtney L Evans, Molly Triggs, Fulton Defour Cureus.2022;[Epub] CrossRef
Schilddrüse und SARS-CoV-2 Georg Zettinig Journal für Klinische Endokrinologie und Stoffwechsel.2022; 15(3): 100. CrossRef
Thyroid diseases are associated with coronavirus disease 2019 infection Yutian Tian, Junyu Zhao, Tingting Wang, Haipeng Wang, Jinming Yao, Song Wang, Yaru Mou Frontiers in Endocrinology.2022;[Epub] CrossRef
The most common persistent symptoms in patients with COVID-19 who were evaluated in the Internal Medicine polyclinic Zeynep KOÇ, Seydahmet AKIN The European Research Journal.2022; : 1. CrossRef
Thyrotropin Levels in Patients with Coronavirus Disease 2019: Assessment during Hospitalization and in the Medium Term after Discharge Abdallah Al-Salameh, Noémie Scherman, Imane Adda, Juliette André, Yoann Zerbib, Julien Maizel, Jean-Daniel Lalau, Etienne Brochot, Claire Andrejak, Rachel Desailloud Life.2022; 12(12): 2014. CrossRef
Clinical assessment of children with long COVID syndrome Réka Garai, Péter Krivácsy, Vivien Herczeg, Fanni Kovács, Bálint Tél, Judit Kelemen, Anna Máthé, Eszter Zsáry, Johanna Takács, Dániel Sándor Veres, Attila J. Szabó Pediatric Research.2022;[Epub] CrossRef
Long COVID in Patients With Mild to Moderate Disease: Do Thyroid Function and Autoimmunity Play a Role? David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Chun Yiu Law, Eunice Ka Hong Leung, Kelvin Kai Wang To, Kathryn Choon Beng Tan, Yu Cho Woo, Ching Wan Lam, Ivan Fan Ngai Hung, Endocrine Practice.2021; 27(9): 894. CrossRef
Hashimoto’s thyroiditis following SARS-CoV-2 infection Rafael Silvestre Knack, Taliê Hanada, Renata Silvestre Knack, Kamilla Mayr BMJ Case Reports.2021; 14(8): e244909. CrossRef
Higher SARS-CoV-2 viral loads correlated with smaller thyroid volumes on ultrasound among male COVID-19 survivors David Tak Wai Lui, Matrix Man Him Fung, Keith Wan Hang Chiu, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Connie Hong Nin Loong, Wade Wei Wong, Cassandra Yuen Yan Lee, Chun Yiu Law, Kelvin K Endocrine.2021; 74(2): 205. CrossRef
SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases Avaniyapuram Kannan Murugan, Ali S Alzahrani Journal of Inflammation Research.2021; Volume 14: 6191. CrossRef
POST-COVID ENDOCRINOPATHY :ABOUT A CASE ENDOCRINOPATHIE POST- COVID :À PROPOS D’UN CAS S. Rafi, G. Elmghari, N, Elansari INDIAN JOURNAL OF APPLIED RESEARCH.2021; : 13. CrossRef
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the parafollicular cells. The diagnostic and therapeutic strategies for the condition are different from those used for well-differentiated thyroid cancer. Since the 2015 American Thyroid Association guidelines for the diagnosis and treatment of MTC, the latest, including the National Comprehensive Cancer Network and European Association for Medical Oncology guidelines have been updated to reflect several recent advances in the management of MTC. Advances in molecular diagnosis and postoperative risk stratification systems have led to individualized treatment and follow-up strategies. Multi-kinase inhibitors, such as vandetanib and cabozantinib, can prolong disease progression-free survival with favorable adverse effects. In addition, potent selective rearranged during transfection (RET) inhibitors (selpercatinib and pralsetinib) have shown a promising efficacy in recent clinical trials. This review summarizes the management of MTC in recent guidelines focused on sporadic MTC.
Citations
Citations to this article as recorded by
Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine Giorgio Treglia, Vittoria Rufini, Arnoldo Piccardo, Alessio Imperiale Seminars in Nuclear Medicine.2023;[Epub] CrossRef
Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect Linnea Højer Wang, Markus Wehland, Petra M. Wise, Manfred Infanger, Daniela Grimm, Michael C. Kreissl International Journal of Molecular Sciences.2023; 24(3): 2312. CrossRef
A proposed grading scheme for predicting recurrence in medullary thyroid cancer based on the Ki67 index and metastatic lymph node ratio Pengfei Xu, Di Wu, Xuekui Liu Endocrine.2023;[Epub] CrossRef
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers Faraat Ali, Kumari Neha, Garima Chauhan Archives of Pharmacal Research.2022; 45(5): 309. CrossRef
Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC) Robin Lockridge, Sima Bedoya, Taryn Allen, Brigitte C. Widemann, Srivandana Akshintala, John Glod, Lori Wiener Children.2022; 9(6): 774. CrossRef
Aggressive clinical course of medullary thyroid microcarcinoma Tamara Janić, Mirjana Stojković, Sanja Klet, Bojan Marković, Beleslin Nedeljković, Jasmina Ćirić, Miloš Žarković Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma.2022; 27(85): 63. CrossRef
Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies Max Czajkowski, Daniel Kaemmerer, Jörg Sänger, Guido Sauter, Ralph M. Wirtz, Stefan Schulz, Amelie Lupp BMC Cancer.2022;[Epub] CrossRef
Metastatic Risk Stratification of 2526 Medullary Thyroid Carcinoma Patients: A Study Based on Surveillance, Epidemiology, and End Results Database Minh-Khang Le, Masataka Kawai, Toru Odate, Huy Gia Vuong, Naoki Oishi, Tetsuo Kondo Endocrine Pathology.2022; 33(3): 348. CrossRef
Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years? Krzysztof Kaliszewski, Maksymilian Ludwig, Bartłomiej Ludwig, Agnieszka Mikuła, Maria Greniuk, Jerzy Rudnicki Cancers.2022; 14(15): 3643. CrossRef
Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells? Giuseppe Fanciulli, Roberta Modica, Anna La Salvia, Federica Campolo, Tullio Florio, Nevena Mikovic, Alice Plebani, Valentina Di Vito, Annamaria Colao, Antongiulio Faggiano Cancers.2022; 14(16): 3991. CrossRef
Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer Davide Saronni, Germano Gaudenzi, Alessandra Dicitore, Silvia Carra, Maria Celeste Cantone, Maria Orietta Borghi, Andrea Barbieri, Luca Mignani, Leo J. Hofland, Luca Persani, Giovanni Vitale Cancers.2022; 14(18): 4442. CrossRef
Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma Marine Sitbon, Porhuoy Chou, Seydou Bengaly, Brigitte Poirot, Marie Laloi-Michelin, Laure Deville, Atanas Pachev, Ahouefa Kowo-Bille, Clement Dumont, Cécile N Chougnet European Thyroid Journal.2022;[Epub] CrossRef
Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation Juan Zhang, Dan Luo, Fang Li, Zhiyi Li, Xiaoli Gao, Jie Qiao, Lin Wu, Miaoling Li, Shao Liang Oxidative Medicine and Cellular Longevity.2021; 2021: 1. CrossRef
THE ROLE OF CALCITONIN IN THE PREOPERATIVE STAGE AS THE PREDICTOR OF MEDULLARY THYROID CANCER METASTASES Volodymyr Palamarchuk , Viktor Smolyar , Oleksandr Tovkay, Oleksandr Nechay, Volodymyr Kuts , Revaz Sichinava , Oleh Mazur Ukrainian Scientific Medical Youth Journal.2021; 127(4): 68. CrossRef
Background Data on the association between coronavirus disease 2019 (COVID-19) and thyroid have been reported, including overt thyrotoxicosis and suppression of thyroid function. We aimed to evaluate the thyroid hormone profile and its association with the prognosis of COVID-19 in Korean patients.
Methods The clinical data of 119 patients with COVID-19, admitted in the Myongji Hospital, Goyang, South Korea, were retrospectively evaluated. The thyroid hormone profiles were analyzed and compared based on disease severity (non-severe disease vs. severe to critical disease). Clinical outcomes were analyzed according to the tertiles of thyroid hormones.
Results Of the 119 patients, 76 (63.9%) were euthyroid, and none presented with overt thyroid dysfunction. Non-thyroidal illness syndrome was the most common manifestation (18.5%), followed by subclinical thyrotoxicosis (14.3%) among patients with thyroid dysfunction. Thyroid stimulating hormone (TSH) and triiodothyronine (T3) levels were significantly lower in patients with severe to critical disease than in those with non-severe disease (P<0.05). Patients in the lowest T3 tertile (<0.77 ng/mL) had higher rates of mechanical ventilation, intensive care unit admission, and death than those in the middle and highest (>1.00 ng/mL) T3 tertiles (P<0.05). COVID-19 patients in the lowest T3 tertile were independently associated with mortality (hazard ratio, 5.27; 95% confidence interval, 1.09 to 25.32; P=0.038) compared with those in the highest T3 tertile.
Conclusion Thyroid dysfunction is common in COVID-19 patients. Changes in serum TSH and T3 levels may be important markers of disease severity in COVID-19. Decreased T3 levels may have a prognostic significance in COVID-19 related outcome.
Citations
Citations to this article as recorded by
Thyroxine changes in COVID-19 pandemic: A systematic review and meta-analysis Ziqi Li, Pengwei Hou, Shuwen Mu, Renzhi Wang, Hui Miao, Ming Feng, He Wang, Wentai Zhang, Yihao Chen, Tianshun Feng, Shousen Wang, Yi Fang Frontiers in Endocrinology.2023;[Epub] CrossRef
The Influence of SARS-CoV-2 Infection on the Thyroid Gland Aleksandra Piekarska, Marta Góral, Marta Kozula, Aleksandra Jawiarczyk-Przybyłowska, Katarzyna Zawadzka, Marek Bolanowski Biomedicines.2023; 11(2): 614. CrossRef
Thyroid Function Abnormalities and Outcomes in Hospitalized Patients
with COVID-19 Infection: A Cross-Sectional Study Deepika Patel, Dukhabandhu Naik, Sadishkumar Kamalanathan, Kadhiravan Tamilarasu, Jayaprakash Sahoo, Ayan Roy, Chandhana Merugu, Varun Suryadevara Hormone and Metabolic Research.2023; 55(03): 169. CrossRef
The Spectrum of Thyroid Function Tests and Autoantibodies During Hospitalization and After Six Months of Discharge in COVID-19 Patients: Does COVID-19 Trigger Autoimmunity? Ziynet Alphan Uc, Pinar Yagcı, Zelal Adibelli, Cevdet Duran Endocrine Research.2023; : 1. CrossRef
The Association Between COVID-19 and Thyroxine Levels: A Meta-Analysis Yiru Chen, Xiuneng Li, Yu Dai, Jingjing Zhang Frontiers in Endocrinology.2022;[Epub] CrossRef
The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea Diagnostics.2022; 12(4): 960. CrossRef
Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19 Stephani C. Wang, Fengmin Zhang, Hui Zhu, Haipeng Yang, Yang Liu, Ping Wang, Vladimir Parpura, Yu-Feng Wang Frontiers in Endocrinology.2022;[Epub] CrossRef
The Association Between FT3 With the Outcome and Inflammation/Coagulopathy/Fibrinolysis of COVID-19 Jiayi Deng, Siye Zhang, Fei Peng, Quan Zhang, Yi Li, Yanjun Zhong Frontiers in Endocrinology.2022;[Epub] CrossRef
Primary hypothyroidism with an episode of ventricular tachycardia in a patient with COVID-19 Pin-Hsu Liao, Yu-Cheng Cheng, Po-Yu Liu, I-Te Lee Medicine.2022; 101(25): e29243. CrossRef
Low triiodothyronine syndrome is associated with stroke‐associated pneumonia Huijun Chen, Minjie Xu, Yezhi Huang, Jincai He, Wenwei Ren European Journal of Clinical Investigation.2022;[Epub] CrossRef
Association of thyroid dysfunction and COVID-19: A systematic review and meta-analysis Mohammad Darvishi, Mohammad Reza Nazer, Hamze Shahali, Majid Nouri Frontiers in Endocrinology.2022;[Epub] CrossRef
The prognostic utility of serum thyrotropin in hospitalized Covid-19 patients: statistical and machine learning approaches E. Pappa, P. Gourna, G. Galatas, M. Manti, A. Romiou, L. Panagiotou, R. Chatzikyriakou, N. Trakas, G. Feretzakis, C. Christopoulos Endocrine.2022;[Epub] CrossRef
Thyrotropin Levels in Patients with Coronavirus Disease 2019: Assessment during Hospitalization and in the Medium Term after Discharge Abdallah Al-Salameh, Noémie Scherman, Imane Adda, Juliette André, Yoann Zerbib, Julien Maizel, Jean-Daniel Lalau, Etienne Brochot, Claire Andrejak, Rachel Desailloud Life.2022; 12(12): 2014. CrossRef
COVID-19 and thyroid function: What do we know so far? Camila Lüdke Rossetti, Juliana Cazarin, Fabio Hecht, Fabyan Esberard de Lima Beltrão, Andrea Cláudia Freitas Ferreira, Rodrigo Soares Fortunato, Helton Estrela Ramos, Denise Pires de Carvalho Frontiers in Endocrinology.2022;[Epub] CrossRef
Thyroid hormone (TH) signaling is strictly regulated by iodothyronine deiodinase activity, which both preserves the circulating levels of the biologically active triiodothyronine (T3) and regulates TH homeostasis at the local level, in a cell- and time-dependent manner. Three deiodinases have been identified—namely iodothyronine deiodinase 1 (DIO1), DIO2, and DIO3—that differ in their catalytic properties and tissue distribution. The deiodinases represent a dynamic system that changes in the different stages of life according to their functions and roles in various cell types and tissues. Deiodinase activity at the tissue level permits cell-targeted fine regulation of TH homeostasis, mediating the activation (DIO1 and DIO2) and inactivation (DIO3) of THs. Deiodinase homeostasis is the driving force that leads T3-target cells towards customized TH signaling, which takes into account both the hormonal circulating levels and the tissue-specific response. This review analyzes the complex role of deiodinases in physiological and pathological contexts, exploring new challenges and opportunities deriving from a deeper knowledge of the dynamics underlying their roles and functions.
Citations
Citations to this article as recorded by
Selenoprotein Gene mRNA Expression Evaluation During Renal Ischemia–Reperfusion Injury in Rats and Ebselen Intervention Effects Yikun Wu, Hua Shi, Yuangao Xu, Rao Wen, Maodi Gong, Guangyi Hong, Shuxiong Xu Biological Trace Element Research.2023; 201(4): 1792. CrossRef
Acute exposure to microcystins affects hypothalamic-pituitary axes of male rats Ting Shi, Lin-Lin Xu, Liang Chen, Jun He, Ye-Ke Wang, Feng Chen, Yang Chen, John P. Giesy, Yu-Ting Wang, Qian-Hui Wu, Wen-Li Xu, Jun Chen, Ping Xie Environmental Pollution.2023; 318: 120843. CrossRef
Thyroid hormone Beta receptor agonists for treatment of kidney disease: A promising agent? Sidar Copur, Furkan Yavuz, Mehmet Kanbay European Journal of Clinical Investigation.2023;[Epub] CrossRef
The ratio of free triiodothyronine to free thyroxine is regulated differently in patients with type 2 diabetes mellitus treated and not treated with sodium glucose cotransporter 2 inhibitors Shuichi Okada, Atsushi Isoda, Hiroto Hoshi, Junichi Okada, Kazuya Okada, Eijiro Yamada, Tsugumichi Saito, Takuya Watanabe, Koji Kikkawa, Kihachi Ohshima Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102704. CrossRef
WITHDRAWN: The effect of deiodinase type-3 gene on the therapeutic response to levothyroxine in a sample of Iraqi hypothyroidism patients Alaa Hashim Mohmmed, Suzanne Jubair, Ban Hoshi Human Gene.2023; : 201142. CrossRef
Subclinical hypothyroidism, outcomes and management guidelines: a narrative review and update of recent literature Bogumila Urgatz, Salman Razvi Current Medical Research and Opinion.2023; : 1. CrossRef
DIO1 Gene Polymorphism Is Associated with Thyroid Profiles and Reproductive Performance in Dairy Cows Olga V. Kostyunina, Olga S. Mityashova, Nikolay V. Bardukov, Olga V. Aleynikova, Irina Y. Lebedeva Agriculture.2023; 13(2): 398. CrossRef
Embryonic thermal manipulation leads growth inhibition and reduced hepatic insulin-like growth factor1 expression due to promoter DNA hypermethylation in broilers Wei Cong, Wanwan Han, Jie Liu, Ruqian Zhao, Lei Wu Poultry Science.2023; 102(4): 102562. CrossRef
Drug Repurposing Patent Applications October–December 2022 Hermann A.M. Mucke ASSAY and Drug Development Technologies.2023;[Epub] CrossRef
Thyroid Dysfunction and COVID-19: The Emerging Role of Selenium in This Intermingled Relationship Francesca Gorini, Laura Sabatino, Alessio Coi, Giorgio Iervasi, Cristina Vassalle International Journal of Environmental Research and Public Health.2022; 19(11): 6912. CrossRef
Associations of bisphenol exposure with thyroid hormones in pregnant women: a prospective birth cohort study in China Huishen Huang, Jun Liang, Peng Tang, Chuanxiang Yu, Haoran Fan, Qian Liao, Jinghua Long, Dongxiang Pan, Xiaoyun Zeng, Shun Liu, Dongping Huang, Xiaoqiang Qiu Environmental Science and Pollution Research.2022; 29(58): 87170. CrossRef
Selenium in Bodily Homeostasis: Hypothalamus, Hormones, and Highways of Communication Pamela Toh, Jessica L. Nicholson, Alyssa M. Vetter, Marla J. Berry, Daniel J. Torres International Journal of Molecular Sciences.2022; 23(23): 15445. CrossRef
Background This study aimed to assess the effects of iodine intake, thyroid function, and their combined effect on the risk of papillary thyroid cancer (PTC) and papillary thyroid microcarcinoma (PTMC).
Methods A case-control study was conducted including 500 community-based controls who had undergone a health check-up, and 446 overall PTC cases (209 PTC and 237 PTMC) from the Thyroid Cancer Longitudinal Study. Urinary iodine concentration (UIC), was used as an indicator of iodine intake, and serum for thyroid function. The risk of PTC and PTMC was estimated using unconditional logistic regression.
Results Excessive iodine intake (UIC ≥220 μg/gCr) was associated with both PTC (odds ratio [OR], 18.13 95% confidence interval [CI], 8.87 to 37.04) and PTMC (OR, 8.02; 95% CI, 4.64 to 13.87), compared to adequate iodine intake (UIC, 85 to 219 μg/gCr). Free thyroxine (T4) levels ≥1.25 ng/dL were associated with PTC (OR, 1.97; 95% CI, 1.36 to 2.87) and PTMC (OR, 2.98; 95% CI, 2.01 to 4.41), compared to free T4 levels of 0.7 to 1.24 ng/dL. Individuals with excessive iodine intake and high free T4 levels had a greatly increased OR of PTC (OR, 43.48; 95% CI, 12.63 to 149.62), and PTMC (OR, 26.96; 95% CI, 10.26 to 70.89), compared to individuals with adequate iodine intake and low free T4 levels.
Conclusion Excessive iodine intake using creatinine-adjusted UIC and high free T4 levels may have a synergistic effect on PTC and PTMC. Considering both iodine intake and thyroid function is important to assess PTC and PTMC risk.
Citations
Citations to this article as recorded by
Association between urinary iodine concentration and the risk of papillary thyroid cancer by sex and age: a case–control study Yerin Hwang, Hyun-Kyung Oh, Jae Hoon Chung, Sun Wook Kim, Jung-Han Kim, Jee Soo Kim, Myung-Hee Shin Scientific Reports.2023;[Epub] CrossRef
Content of Copper, Iron, Iodine, Rubidium, Strontium and Zinc in Thyroid Malignant Nodules and Thyroid Tissue adjacent to Nodules Vladimir Zaichick, Qiping Dong Journal of Clinical and Diagnostic Pathology.2022; 1(4): 7. CrossRef
Distinguish Thyroid Malignant from Benign Alterations using Trace Element Contents in Nodular Tissue determined by Neutron Activation and Inductively Coupled Plasma Mass Spectrometry Vladimir Zaichick Journal of Clinical and Diagnostic Pathology.2022; 1(4): 18. CrossRef
Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer Tung Hoang, Eun Kyung Lee, Jeonghee Lee, Yul Hwangbo, Jeongseon Kim Endocrinology and Metabolism.2022; 37(3): 513. CrossRef
Iodine nutrition and papillary thyroid cancer Xueqi Zhang, Fan Zhang, Qiuxian Li, Chuyao Feng, Weiping Teng Frontiers in Nutrition.2022;[Epub] CrossRef
The relationship between urinary iodine concentration and papillary thyroid cancer: A systematic review and meta-analysis Xueqi Zhang, Fan Zhang, Qiuxian Li, Renaguli Aihaiti, Chuyao Feng, Deshi Chen, Xu Zhao, Weiping Teng Frontiers in Endocrinology.2022;[Epub] CrossRef
Screening and validation of lymph node metastasis risk-factor genes in papillary thyroid carcinoma Qiaoyue Zhang, Jing Li, Hengyan Shen, Xinyu Bai, Tao Zhang, Ping Liu Frontiers in Endocrinology.2022;[Epub] CrossRef
Diagnosis of Thyroid Malignancy using Levels of Chemical Element Contents in Nodular Tissue Vladimir Zaichick Journal of Health Care and Research.2022; 3(1): 16. CrossRef
Associations of Habitual Mineral Intake with New-Onset Prediabetes/Diabetes after Acute Pancreatitis Claire F. Norbitt, Wandia Kimita, Juyeon Ko, Sakina H. Bharmal, Maxim S. Petrov Nutrients.2021; 13(11): 3978. CrossRef
Subclinical hypothyroidism (sHypo) is defined as normal serum free thyroid hormone levels coexisting with elevated serum thyroid-stimulating hormone (TSH) levels. sHypo is a common condition observed in clinical practice with several unique features. Its diagnosis should be based on an understanding of geographic and demographic differences in biochemical criteria versus a global reference range for TSH that is based on the 95% confidence interval of a healthy population. During the differential diagnosis, it is important to remember that a considerable proportion of sHypo cases are transient and reversible in nature; the focus is better placed on persistent or progressive forms, which mainly result from chronic autoimmune thyroiditis. Despite significant evidence documenting the health impacts of sHypo, the effects of levothyroxine treatment (LT4-Tx) in patients with sHypo remains controversial, especially in patients with grade 1 sHypo and older adults. Existing evidence suggests that it is reasonable to refrain from immediate LT4-Tx in most patients if they are closely monitored, except in women who are pregnant or in progressive cases. Future research is needed to further characterize the risks and benefits of LT4-Tx in different patient cohorts.
Citations
Citations to this article as recorded by
Subclinical hypothyroidism, outcomes and management guidelines: a narrative review and update of recent literature Bogumila Urgatz, Salman Razvi Current Medical Research and Opinion.2023; 39(3): 351. CrossRef
Indicator of thyroid hormones in newborns from mothers with diffuse-endemic goiter G. T. Makhkamova, Sh. T. Turdieva Meditsinskiy sovet = Medical Council.2023; (1): 212. CrossRef
Comparison of Five Different Criteria for Diagnosis of Subclinical Hypothyroidism in a Large-Scale Chinese Population Yan-song Zheng, Sheng-yong Dong, Yan Gong, Jia-hong Wang, Fei Wang, Qiang Zeng Frontiers in Endocrinology.2022;[Epub] CrossRef
Subclinical Hypothyroidism and Cognitive Impairment Jung-Min Pyun, Young Ho Park, SangYun Kim Journal of Alzheimer's Disease.2022; 88(2): 757. CrossRef
Effect of Levothyroxine Supplementation on the Cardiac Morphology and Function in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis Xichang Wang, Haoyu Wang, Qiuxian Li, Ping Wang, Yumin Xing, Fan Zhang, Jiashu Li, Zhongyan Shan The Journal of Clinical Endocrinology & Metabolism.2022; 107(9): 2674. CrossRef
Natural history of subclinical hypothyroidism and prognostic factors for the development of overt hypothyroidism: Tehran Thyroid Study (TTS) A. Amouzegar, M. Dehghani, H. Abdi, L. Mehran, S. Masoumi, F. Azizi Journal of Endocrinological Investigation.2022; 45(12): 2353. CrossRef
Retrospective cohort analysis comparing changes in blood glucose level and body composition according to changes in thyroid‐stimulating hormone level Hyunah Kim, Da Young Jung, Seung‐Hwan Lee, Jae‐Hyoung Cho, Hyeon Woo Yim, Hun‐Sung Kim Journal of Diabetes.2022; 14(9): 620. CrossRef
Eun Kyung Lee, Yea Eun Kang, Young Joo Park, Bon Seok Koo, Ki-Wook Chung, Eu Jeong Ku, Ho-Ryun Won, Won Sang Yoo, Eonju Jeon, Se Hyun Paek, Yong Sang Lee, Dong Mee Lim, Yong Joon Suh, Ha Kyoung Park, Hyo-Jeong Kim, Bo Hyun Kim, Mijin Kim, Sun Wook Kim, Ka Hee Yi, Sue K. Park, Eun-Jae Jung, June Young Choi, Ja Seong Bae, Joon Hwa Hong, Kee-Hyun Nam, Young Ki Lee, Hyeong Won Yu, Sujeong Go, Young Mi Kang, MASTER study group
Endocrinol Metab. 2021;36(3):574-581. Published online May 26, 2021
Background Postoperative thyroid stimulating hormone (TSH) suppression therapy is recommended for patients with intermediate- and high-risk differentiated thyroid cancer to prevent the recurrence of thyroid cancer. With the recent increase in small thyroid cancer cases, the extent of resection during surgery has generally decreased. Therefore, questions have been raised about the efficacy and long-term side effects of TSH suppression therapy in patients who have undergone a lobectomy.
Methods This is a multicenter, prospective, randomized, controlled clinical trial in which 2,986 patients with papillary thyroid cancer are randomized into a high-TSH group (intervention) and a low-TSH group (control) after having undergone a lobectomy. The principle of treatment includes a TSH-lowering regimen aimed at TSH levels between 0.3 and 1.99 μIU/mL in the low-TSH group. The high-TSH group targets TSH levels between 2.0 and 7.99 μIU/mL. The dose of levothyroxine will be adjusted at each visit to maintain the target TSH level. The primary outcome is recurrence-free survival, as assessed by neck ultrasound every 6 to 12 months. Secondary endpoints include disease-free survival, overall survival, success rate in reaching the TSH target range, the proportion of patients with major cardiovascular diseases or bone metabolic disease, the quality of life, and medical costs. The follow-up period is 5 years.
Conclusion The results of this trial will contribute to establishing the optimal indication for TSH suppression therapy in low-risk papillary thyroid cancer patients by evaluating the benefit and harm of lowering TSH levels in terms of recurrence, metabolic complications, costs, and quality of life.
Citations
Citations to this article as recorded by
ASO Author Reflections: Active Surveillance may be Possible in Patients with T1b Papillary Thyroid Carcinoma Over 55 Years of Age Without High-Risk Features on Preoperative Examinations Ho-Ryun Won, Eonju Jeon, Da Beom Heo, Jae Won Chang, Minho Shong, Je Ryong Kim, Hyemi Ko, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Kyong Hye Joung, Ji Min Kim, Younju Lee, Sung-Woo Kim, Young Ju Jeong, Yong Bae Ji, Kyung Tae, Bon Seok Koo Annals of Surgical Oncology.2023;[Epub] CrossRef
Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer Arash Abiri, Khodayar Goshtasbi, Sina J. Torabi, Edward C. Kuan, William B. Armstrong, Tjoson Tjoa, Yarah M. Haidar Otolaryngology–Head and Neck Surgery.2023;[Epub] CrossRef
Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis Timothy M Ullmann, Maria Papaleontiou, Julie Ann Sosa The Journal of Clinical Endocrinology & Metabolism.2023; 108(2): 271. CrossRef
Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma Mi Rye Bae, Sung Hoon Nam, Jong-Lyel Roh, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim Endocrine.2022; 75(2): 487. CrossRef
Age-Dependent Clinicopathological Characteristics of Patients with T1b Papillary Thyroid Carcinoma: Implications for the Possibility of Active Surveillance Ho-Ryun Won, Eonju Jeon, Da Beom Heo, Jae Won Chang, Minho Shong, Je Ryong Kim, Hyemi Ko, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Kyong Hye Joung, Ji Min Kim, Younju Lee, Sung-Woo Kim, Young Ju Jeong, Yong Bae Ji, Kyung Tae, Bon Seok Koo Annals of Surgical Oncology.2022;[Epub] CrossRef
The Concept of Economic Evaluation and Its Application in Thyroid Cancer Research Kyungsik Kim, Mijin Kim, Woojin Lim, Bo Hyun Kim, Sue K. Park Endocrinology and Metabolism.2021; 36(4): 725. CrossRef
Background The detrimental effects of excessive thyroid hormone on glucose metabolism have been widely investigated. However, the risk of diabetes in patients with long-standing hyperthyroidism, especially according to treatment modality, remains uncertain, with few longitudinal studies.
Methods The risk of diabetes in patients with Graves’ disease treated with antithyroid drugs (ATDs) for longer than the conventional duration (≥2 years) was compared with that in age-and sex-matched controls. The risk was further compared according to subsequent treatment modalities after a 24-month course of ATD: continuation of ATD (ATD group) vs. radioactive iodine ablation (RIA) group.
Results A total of 4,593 patients were included. Diabetes was diagnosed in 751 (16.3%) patients over a follow-up of 7.3 years. The hazard ratio (HR) for diabetes, after adjusting for various known risk factors, was 1.18 (95% confidence interval [CI], 1.10 to 1.28) in patients with hyperthyroidism. Among the treatment modality groups, the RIA group (n=102) had a higher risk of diabetes than the ATD group (n=4,491) with HR of 1.56 (95% CI, 1.01 to 2.42). Further, the risk of diabetes increased with an increase in the ATD treatment duration (P for trend=0.019).
Conclusion The risk of diabetes was significantly higher in patients with long-standing Graves’ disease than in the general population, especially in patients who underwent RIA and prolonged ATD treatment. Special attention to hyperglycemia during follow-up along with effective control of hyperthyroidism may be necessary to reduce the risk of diabetes in these patients.
Citations
Citations to this article as recorded by
Control of Thyroid Dysfunction in Spanish Population Registered in
the Primary Care Clinical Database: An Analysis of the Proportion of Patients
with Thyrotropin Values Outside the Reference Range Juan J. Díez, Pedro Iglesias Hormone and Metabolic Research.2023; 55(03): 184. CrossRef
Prevalence of thyroid dysfunction and its relationship to income level and employment status: a nationwide population-based study in Spain Juan J. Díez, Pedro Iglesias Hormones.2023;[Epub] CrossRef
Prevalencia de diabetes en personas con disfunción tiroidea Juan J. Díez, Pedro Iglesias Medicina Clínica.2022;[Epub] CrossRef
Metabolite Changes during the Transition from Hyperthyroidism to Euthyroidism in Patients with Graves’ Disease Ho Yeop Lee, Byeong Chang Sim, Ha Thi Nga, Ji Sun Moon, Jingwen Tian, Nguyen Thi Linh, Sang Hyeon Ju, Dong Wook Choi, Daiki Setoyama, Hyon-Seung Yi Endocrinology and Metabolism.2022; 37(6): 891. CrossRef
Diabetes and Hyperthyroidism: Is There a Causal Link? Sang Yong Kim Endocrinology and Metabolism.2021; 36(6): 1175. CrossRef
Background High-density lipoprotein cholesterol (HDL-C) plays an important role in the reverse cholesterol transport pathway and prevents atherosclerosis-mediated disease. It has also been suggested that HDL-C may be a protective factor against cancer. However, an inverse correlation between HDL-C and cancer has not been established, and few studies have explored thyroid cancer.
Methods The study participants received health checkups provided by the Korean National Health Insurance Service from 2009 to 2013 and were followed until 2019. Considering the variability of serum HDL-C level, low HDL-C level was analyzed by grouping based on four consecutive health checkups. The data analysis was performed using univariate and multivariate Cox proportional hazard regression models.
Results A total of 3,134,278 total study participants, thyroid cancer occurred in 16,129. In the crude model, the hazard ratios for the association between repeatedly measured low HDL-C levels and thyroid cancer were 1.243, 1.404, 1.486, and 1.680 (P for trend <0.01), respectively, which were significant even after adjusting for age, sex, lifestyle factors, and metabolic diseases. The subgroup analysis revealed that low HDL-C levels likely had a greater impact on the group of patients with central obesity (P for interaction= 0.062), high blood pressure (P for interaction=0.057), impaired fasting glucose (P for interaction=0.051), and hyperlipidemia (P for interaction=0.126).
Conclusion Repeatedly measured low HDL-C levels can be considered a risk factor for cancer as well as vascular disease. Low HDL-C levels were associated with the risk of thyroid cancer, and this correlation was stronger in a metabolically unhealthy population.
Citations
Citations to this article as recorded by
Carbohydrate, Lipid, and Apolipoprotein Biomarkers in Blood and Risk of Thyroid Cancer: Findings from the AMORIS Cohort Xue Xiao, Yi Huang, Fetemeh Sadeghi, Maria Feychting, Niklas Hammar, Fang Fang, Zhe Zhang, Qianwei Liu Cancers.2023; 15(2): 520. CrossRef
Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab Fei Wang, Luo Lu, HuiJuan Chen, Yanhua Yue, Yanting Sun, Feng Yan, Bai He, Rongrong Lin, Weiying Gu Annals of Hematology.2023; 102(2): 393. CrossRef
Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee Endocrinology and Metabolism.2023; 38(1): 10. CrossRef
Risk factors and diagnostic prediction models for papillary thyroid carcinoma Xiaowen Zhang, Yuyang Ze, Jianfeng Sang, Xianbiao Shi, Yan Bi, Shanmei Shen, Xinlin Zhang, Dalong Zhu Frontiers in Endocrinology.2022;[Epub] CrossRef
Exposure to multiple trace elements and thyroid cancer risk in Chinese adults: A case-control study Jia-liu He, Hua-bing Wu, Wen-lei Hu, Jian-jun Liu, Qian Zhang, Wei Xiao, Ming-jun Hu, Ming Wu, Fen Huang International Journal of Hygiene and Environmental Health.2022; 246: 114049. CrossRef
The fifth edition of the World Health Organization (WHO) histologic classification of thyroid neoplasms released in 2022 includes newly recognized tumor types, subtypes, and a grading system. Follicular cell-derived neoplasms are categorized into three families (classes): benign tumors, low-risk neoplasms, and malignant neoplasms. The terms “follicular nodular disease” and “differentiated high-grade thyroid carcinoma” are introduced to account for multifocal hyperplastic/neoplastic lesions and differentiated thyroid carcinomas with high-grade features, respectively. The term “Hürthle cells” is replaced with “oncocytic cells.” Invasive encapsulated follicular and cribriform morular variants of papillary thyroid carcinoma (PTC) are now redefined as distinct tumor types, given their different genetic alterations and clinicopathologic characteristics from other PTC subtypes. The term “variant” to describe a subclass of tumor has been replaced with the term “subtype.” Instead, the term “variant” is reserved to describe genetic alterations. A histologic grading system based on the mitotic count, necrosis, and/or the Ki67 index is used to identify high-grade follicular-cell derived carcinomas and medullary thyroid carcinomas. The 2022 WHO classification introduces the following new categories: “salivary gland-type carcinomas of the thyroid” and “thyroid tumors of uncertain histogenesis.” This review summarizes the major changes in the 2022 WHO classification and their clinical relevance.
Citations
Citations to this article as recorded by
Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma Chan Kwon Jung, Shipra Agarwal, Jen-Fan Hang, Dong-Jun Lim, Andrey Bychkov, Ozgur Mete Endocrine Pathology.2023; 34(1): 1. CrossRef
Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer Yuji Nagayama, Koichiro Hamada Metabolites.2022; 12(12): 1214. CrossRef
Developments to improve outcomes in thyroid surgery Thomas J. Musholt Innovative Surgical Sciences.2022; 7(3-4): 77. CrossRef
The relationship of the clinicopathological characteristics and treatment results of post-Chornobyl papillary thyroid microcarcinomas with the latency period and radiation exposure Tetiana Bogdanova, Serhii Chernyshov, Liudmyla Zurnadzhy, Tatiana I. Rogounovitch, Norisato Mitsutake, Mykola Tronko, Masahiro Ito, Michael Bolgov, Sergii Masiuk, Shunichi Yamashita, Vladimir A. Saenko Frontiers in Endocrinology.2022;[Epub] CrossRef
Graves’ disease is associated with thyrotropin (TSH) receptor stimulating antibody, for which there is no therapeutic agent. This disease is currently treated through inhibition of thyroid hormone synthesis or destruction of the thyroid gland. Recurrence after antithyroid drug (ATD) treatment is common. Recent studies have shown that the longer is the duration of use of ATD, the higher is the remission rate. Considering the relationship between clinical outcomes and iodine intake, recurrence of Graves’ disease is more common in iodine-deficient areas than in iodine-sufficient areas. Iodine restriction in an iodine-excessive area does not improve the effectiveness of ATD or increase remission rates. Recently, Danish and Korean nationwide studies noted significantly higher prevalence of birth defects in newborns exposed to ATD during the first trimester compared to that of those who did not have such exposure. The prevalence of birth defects was lowest when propylthiouracil (PTU) was used and decreased by only 0.15% when methimazole was changed to PTU in the first trimester. Therefore, it is best not to use ATD in the first trimester or to change to PTU before pregnancy.
Citations
Citations to this article as recorded by
Выраженность окислительного стресса и энзиматическая активность нейтрофилов крови у пациентов с болезнью Грейвса в зависимости от компенсации гипертиреоза М. А. Дудина, С. А. Догадин, А. А. Савченко, И. И. Гвоздев Ateroscleroz.2023; 18(4): 411. CrossRef
Usefulness of Real-Time Quantitative Microvascular Ultrasonography for Differentiation of Graves’ Disease from Destructive Thyroiditis in Thyrotoxic Patients Han-Sang Baek, Ji-Yeon Park, Chai-Ho Jeong, Jeonghoon Ha, Moo Il Kang, Dong-Jun Lim Endocrinology and Metabolism.2022; 37(2): 323. CrossRef
The chemiluminescent and enzymatic activity of blood neutrophils in patients with Graves' disease depending on hyperthyroidism compensation M. A. Dudina, A. A. Savchenko, S. A. Dogadin, I. I. Gvozdev Clinical and experimental thyroidology.2022; 18(1): 4. CrossRef
Risk of Diabetes in Patients with Long-Standing Graves’ Disease: A Longitudinal Study Eyun Song, Min Ji Koo, Eunjin Noh, Soon Young Hwang, Min Jeong Park, Jung A Kim, Eun Roh, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo Endocrinology and Metabolism.2021; 36(6): 1277. CrossRef
Background The association between Graves’ disease (GD) and co-existing thyroid cancer is still controversial and most of the previously reported data have been based on surgically treated GD patients. This study investigated the clinicopathological findings and prognosis of concomitant thyroid cancer in GD patients in the era of widespread application of ultrasonography.
Methods Data of GD patients who underwent thyroidectomy for thyroid cancer between 2010 and 2019 in three tertiary hospitals in South Korea (Asan Medical Center, Chonnam National University Hwasun Hospital, and Pusan National University Hospital) were collected and analyzed retrospectively. In the subgroup analysis, aggressiveness and clinical outcomes of thyroid cancer were compared nodular GD and non-nodular GD groups according to the presence or absence of the thyroid nodules other than thyroid cancer (index nodules).
Results Of the 15,159 GD patients treated at the hospitals during the study period, 262 (1.7%) underwent thyroidectomy for coexisting thyroid cancer. Eleven patients (4.2%) were diagnosed with occult thyroid cancer and 182 patients (69.5%) had microcarcinomas. No differences in thyroid cancer aggressiveness, ultrasonographic findings, or prognosis were observed between the nodular GD and non-nodular GD groups except the cancer subtype. In the multivariate analysis, only lymph node (LN) metastasis was an independent prognostic factor for recurrent/persistent disease of thyroid cancer arising in GD (P=0.020).
Conclusion The prevalence of concomitant thyroid cancer in GD patients was considerably lower than in previous reports. The clinical outcomes of thyroid cancer in GD patients were also excellent but, more cautious follow-up is necessary for patients with LN metastasis in the same way as for thyroid cancer in non-GD patients.
Citations
Citations to this article as recorded by
Outcomes of Surgical Treatment for Graves’ Disease: A Single-Center Experience of 216 Cases Hanxing Sun, Hui Tong, Xiaohui Shen, Haoji Gao, Jie Kuang, Xi Chen, Qinyu Li, Weihua Qiu, Zhuoran Liu, Jiqi Yan Journal of Clinical Medicine.2023; 12(4): 1308. CrossRef
Predisposition to and Prognosis of Thyroid Cancer May Not Be Affected by Graves’ Disease, But Some Questions Still Remain Yanrui Huang, Haixia Guan Clinical Thyroidology.2022; 34(2): 59. CrossRef
A Comparative Follow-Up Study of Patients with Papillary Thyroid Carcinoma Associated or Not with Graves’ Disease Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Maria Rondini, Angela Spanu, Giuseppe Madeddu Diagnostics.2022; 12(11): 2801. CrossRef
Circulating concentrations of thyrotropin (TSH) and thyroxine (T4) are tightly regulated. Each individual has setpoints for TSH and free T4 which are genetically determined, and subject to environmental and epigenetic influence. Pituitary-thyroid axis setpoints are probably established in utero, with maturation of thyroid function continuing until late gestation. From neonatal life (characterized by a surge of TSH and T4 secretion) through childhood and adolescence (when free triiodothyronine levels are higher than in adults), thyroid function tests display complex, dynamic patterns which are sexually dimorphic. In later life, TSH increases with age in healthy older adults without an accompanying fall in free T4, indicating alteration in TSH setpoint. In view of this, and evidence that mild subclinical hypothyroidism in older people has no health impact, a strong case can be made for implementation of age-related TSH reference ranges in adults, as is routine in children.
Citations
Citations to this article as recorded by
DNA Methylation in Autoimmune Thyroid Disease Nicole Lafontaine, Scott G Wilson, John P Walsh The Journal of Clinical Endocrinology & Metabolism.2023; 108(3): 604. CrossRef
A Causality between Thyroid Function and Bone Mineral Density in Childhood: Abnormal Thyrotropin May Be Another Pediatric Predictor of Bone Fragility Dongjin Lee, Moon Bae Ahn Metabolites.2023; 13(3): 372. CrossRef
Background The management of cytologically indeterminate thyroid nodules is challenging for clinicians. This study aimed to compare the diagnostic performance of the Korean Thyroid Imaging Reporting and Data Systems (K-TIRADS) with that of the American College of Radiology (ACR)-TIRADS for predicting the malignancy risk of indeterminate thyroid nodules.
Methods Thyroid nodules diagnosed by fine-needle aspiration (FNA) followed by surgery or core needle biopsy at a single referral hospital were enrolled.
Results Among 200 thyroid nodules, 78 (39.0%) nodules were classified as indeterminate by FNA (Bethesda category III, IV, and V), and 114 (57.0%) nodules were finally diagnosed as malignancy by surgery or core needle biopsy. The area under the curve (AUC) was higher for FNA than for either TIRADS system in all nodules, while all three methods showed similar AUCs for indeterminate nodules. However, for Bethesda category III nodules, applying K-TIRADS 5 significantly increased the risk of malignancy compared to a cytological examination alone (50.0% vs. 26.5%, P=0.028), whereas applying ACR-TIRADS did not lead to a change.
Conclusion K-TIRADS and ACR-TIRADS showed similar diagnostic performance in assessing indeterminate thyroid nodules, and K-TIRADS had beneficial effects for malignancy prediction in Bethesda category III nodules.
Citations
Citations to this article as recorded by
Diagnostic Performance of Various Ultrasound Risk Stratification Systems for Benign and Malignant Thyroid Nodules: A Meta-Analysis Ji-Sun Kim, Byung Guk Kim, Gulnaz Stybayeva, Se Hwan Hwang Cancers.2023; 15(2): 424. CrossRef
The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules Saad M. Alqahtani, Saif S. Al-Sobhi, Mohammed A. Alturiqy, Riyadh I. Alsalloum, Hindi N. Al-Hindi Journal of Taibah University Medical Sciences.2023; 18(3): 506. CrossRef
Diagnostic Performance of ACR and Kwak TI-RADS for Benign and Malignant Thyroid Nodules: An Update Systematic Review and Meta-Analysis Yun Jin Kang, Gulnaz Stybayeya, Ju Eun Lee, Se Hwan Hwang Cancers.2022; 14(23): 5961. CrossRef
Comparison of Thyroid Imaging Reporting and Data Systems in Malignancy Risk Stratification of Indeterminate Thyroid Nodules Bo Hyun Kim Endocrinology and Metabolism.2021; 36(5): 974. CrossRef
Heera Yang, Hyunju Park, Hyun Jin Ryu, Jung Heo, Jung-Sun Kim, Young Lyun Oh, Jun-Ho Choe, Jung Han Kim, Jee Soo Kim, Hye Won Jang, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung
Endocrinol Metab. 2022;37(4):652-663. Published online July 22, 2022
Background Telomerase reverse transcriptase (TERT) promoter mutations are associated with increased recurrence and mortality in patients with thyroid carcinoma. Previous studies on TERT promoter mutations were retrospectively conducted on a limited number of patients.
Methods We prospectively collected data on all consecutive patients who underwent thyroid carcinoma surgery between January 2019 and December 2020 at the Samsung Medical Center, Seoul, Korea. We included 2,092 patients with thyroid carcinoma.
Results Of 2,092 patients, 72 patients (3.4%) had TERT promoter mutations. However, the frequency of TERT promoter mutations was 0.5% in papillary thyroid microcarcinoma (PTMC) ≤1 cm and it was 5.8% in papillary thyroid carcinoma (PTC) >1 cm. The frequency of TERT promoter mutations was significantly associated with older age at diagnosis (odds ratio [OR], 1.12; P<0.001), larger primary tumor size (OR, 2.02; P<0.001), and aggressive histological type (OR, 7.78 in follicular thyroid carcinoma; OR, 10.33 in poorly differentiated thyroid carcinoma; OR, 45.92 in anaplastic thyroid carcinoma; P<0.001). Advanced T stage, advanced N stage, and distant metastasis at diagnosis were highly prevalent in mutated thyroid cancers. However, initial distant metastasis was not present in patients with TERT promoter mutations in PTMC. Although the C228T mutation was more highly detected than the C250T mutation (64 cases vs. 7 cases), there were no significant clinicopathological differences.
Conclusion This study is the first attempt to investigate the frequency of TERT promoter mutations in a real-world setting. The frequency of TERT promoter mutations in PTC was lower than expected, and in PTMC, young patients, and female patients, the frequency was very low.
Citations
Citations to this article as recorded by
Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer Tsung-Jang Yeh, Chi-Wen Luo, Jeng-Shiun Du, Chien-Tzu Huang, Min-Hung Wang, Tzer-Ming Chuang, Yuh-Ching Gau, Shih-Feng Cho, Yi-Chang Liu, Hui-Hua Hsiao, Li-Tzong Chen, Mei-Ren Pan, Hui-Ching Wang, Sin-Hua Moi Biomedicines.2023; 11(3): 691. CrossRef
TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea Min Jhi Kim, Jin Kyong Kim, Gi Jeong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Woong Youn Chung, Daham Kim, Kee-Hyun Nam Cancers.2022; 14(19): 4928. CrossRef
Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients (Endocrinol Metab 2022;37:652-63, Heera Yang et al.) Hyunju Park, Jae Hoon Chung Endocrinology and Metabolism.2022; 37(6): 949. CrossRef
Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients (Endocrinol Metab 2022;37:652-63, Heera Yang et al.) Sue Youn Kim, Chan Kwon Jung Endocrinology and Metabolism.2022; 37(6): 947. CrossRef